Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignancies, currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Richter Syndrome
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• BGB-16673

Snippet

Sponsor: BeiGene | Conditions: B-cell Malignancy, Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING